REBEC

Public trial

Oral splint and counselling for the treatment of chronic facial pain

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Cardiac responses during rehabilitation in patients undergoing cardiac surgery

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of exercise in ovseweight nondialyis dependent chronic kidney disease patients.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison of methods of oral rehydration therapy in children with acute diarrhea.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of a type of therapy for the treatment of vaginal pain during intercourse.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of two types of implants installed in the jaw

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Analysis of the cardiac frequency and oxygenation during sleep in patients with the Obstructive Sleep Apnea Syndrome

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Ocular surface evaluation in ocular hypertension or inicial glaucoma patients treated with drops.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of dressing for central venous catheter

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of drug therapy in the treatment of migraine

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Homeopathic medicines as complementary treatment of cocaine dependence.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Treatment of severe stroke guided by parameters regarding brain protection and neurological recovery

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Effects of pulmonary re-expansion maneuver on patients receiving mechanical ventilation

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of electrical stimulation and ventilatory muscle training in patients with kidney disease on hemodialysis

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of the ultrasound therapy on venous ulcer healing

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of mirror therapy in upper limb of young individuals with cerebral palsy and cerebral vascular accident

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Acupuncture in Multiple Sclerosis

Date of registration: 04/16/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Effect of physical therapy in the diaphragm of the elderly on the function of the lungs

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Analysis of low level laser therapy in the treatment of patients with fibromyalgia

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The use of carbon dioxide (CO2) as a contrast medium for performing endovascular procedures

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

01/16/2026

Brazilian Appointed by WHO as Director of Special Program on Tropical Diseases

01/16/2026 | Carolina Medina | Health Business

https://www.saudebusiness.com/saude-publica/brasileiro-e-nomeado-pela-oms-como-diretor-de-programa-especial-sobre-doencas-tropicais/

Marcus Lacerda will officially assume the program at the beginning of March this year.

The World Health Organization (WHO) announced the new director of the Special Program for Research and Training in Tropical Diseases (TDR). It is the infectious disease physician and public health researcher from Fiocruz, Marcus Vinicius Guimarães Lacerda, who will officially assume the position in March.

This is the second time a Brazilian has directed the TDR. The first was the physician and biophysicist Carlos Morel, former president of Fiocruz.

The appointment was made by WHO Director-General Tedros Adhanom during a selection panel endorsed by members of the Joint Coordinating Council (JCB) and the co-sponsors of the Treaty on the Reform of Development (TDR), including the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP), the World Bank, and the WHO.

Learn about the new director's background

Born in Taguatinga, near Brasília (DF), Lacerda graduated in Medicine from the University of Brasília (UnB), specializing in Infectious Diseases at the Dr. Heitor Vieira Dourado Tropical Medicine Foundation (FMT-HVD) in Amazonas, a period during which he began working with remote communities in the Amazon, tackling malaria and other tropical diseases.

The new director is also a former president of the Brazilian Society of Tropical Medicine (SBMT) and has become an international leader in malaria research, especially in the management and elimination of Plasmodium vivax. Currently, he coordinates the Carlos…

01/16/2026

Confusion Over ‘Cancellation’ of Controversial Hepatitis B Trial in Guinea-Bissau

01/16/2026 | Kerry Cullinan | Health Policy Watch

https://healthpolicy-watch.news/confusion-over-cancellation-of-controversial-hepatitis-b-trial-in-guinea-bissau/

A controversial clinical trial on the effects of the hepatitis B vaccine on babies in Guinea-Bissau has been “cancelled”, according to Dr Yap Boum of Africa Centres for Disease Control and Prevention (CDC).

However, this has been contested by the US Department of Health and Human Services (HHS), which is funding a Danish group to conduct the study, according to CIDRAP.

An HHS official told CIDRAP that researchers are still working on the study protocol, the official said, adding, “we are proceeding as planned.”

But Boum told a media briefing on Thursday that there were “ethical challenges” with the trial design, and Africa CDC had engaged with the health ministry of Guinea-Bissau about it.

“Our information is that the study has been cancelled,” said Boum, who added that while the continent needs research about vaccines, including hepatitis B, “this has to be done within the norms, so we are glad that at this point, the study has been cancelled”.

Boum, Africa CDC’s deputy incident manager for mpox who often stands in for the Africa CDC Director-General at media briefings, added that there would be “more engagement” with Guinea-Bissau.

The US Centers for Disease Control and Prevention (CDC) awarded Bandim Health Project at the University of Southern Denmark a $1,6 million five-year grant to study the “optimal timing and delivery of monovalent hepatitis B vaccinations on newborns in Guinea-Bissau”, according to the US HHS federal register.

The trial aimed to enrol 14,000 newborns in a “randomized…

01/16/2026

Harvard debates legalization of psychedelics with a focus on regulation and scientific evidence

01/16/2026 | Carol Alencar | Sechat

https://sechat.com.br/noticia/harvard-debate-legalizacao-de-psicodelicos-com-foco-em-regulacao-e-evidencias-cientificas

An interdisciplinary panel held at Harvard University brought together experts in law, ethics, science, and drug policy to discuss the possibility of opening legal avenues for the therapeutic use of psychedelics in the United States. The event addressed whether the legalization of these compounds should move forward quickly or wait for more scientific evidence and robust regulatory mechanisms.

During the discussions, researchers pointed to a tension between growing social demand and the need for state oversight capable of keeping pace with this movement. Some participants emphasized that broad terms such as “psychedelics” encompass very different substances and contexts, which can lead to inflated expectations or underestimation of risks if policies are formulated without a solid evidence base.

Researchers and debaters also highlighted that most psychedelics remain illegal under US federal law, despite advances in clinical research exploring their potential in the treatment of mood disorders and substance use. Studies indicate progress in compounds such as psilocybin, currently in advanced stages of clinical trials, but still without full approval from regulatory agencies such as the FDA.

Risks, evidence, and access models
At the meeting, arguments for and against accelerating legalization were presented. One participant, a military veteran, argued that blocking access in therapeutic contexts could harm individuals in intense distress, citing personal experiences with substances such as ibogaine.

On the other hand, medical ethics experts emphasized that any promise of therapeutic benefit must be proven…

01/16/2026

Anvisa faces efficiency challenge in 2026 and seeks regulatory agility

01/15/2026 | Vilhena Soares | Jota

https://www.jota.info/saude/anvisa-tem-eficiencia-como-desafio-de-2026-e-busca-agilidade-regulatoria

The main objective is to reduce the backlog of applications, whether for research authorization or for the registration of medicines and products

The Brazilian Health Regulatory Agency (Anvisa) will face urgent regulatory challenges throughout 2026. The main objective will be to continue the strategy, begun in the previous year, to reduce the backlog of applications, whether for clinical research authorization or for the registration of medicines and products.

But there are other important issues, such as updating the rules for hospital construction projects and advanced therapies. The regulation of medical cannabis cultivation and the impasse over drug and food advertising in the Supreme Court (ADI 7788) are also on the list of highlights.

The agency's collegiate board meetings begin on January 28.

In addition to these challenges, the end of Director Rômison Mota's term in December will leave a seat open on the Collegiate Board (DICOL), which will be filled in 2026. Today, the fourth board position is temporarily occupied by Marcelo Matos Moreira, a career civil servant at the agency.

Reducing queues
In November, Anvisa announced a series of actions to speed up the analysis of clinical research and registration applications for drugs and biological products.

The set of measures includes differentiated drug analysis strategies, such as grouping products that have the same technical/clinical report and the same Active Pharmaceutical Ingredient (API), in addition to expanding the use of regulatory trust.

Monitoring
In 2026, the agency is expected to monitor the performance…

01/15/2026

From Fragmented to Unified: How Flex Databases Is Rewiring Clinical Operations for the AI Era

01/15/2026 | Clinical Trials Arena

https://www.clinicaltrialsarena.com/excellence-in-focus/flex-databases-eclinical-platform-ai-trials/?cf-view

With pressure mounting to shorten timelines and tighten oversight, Flex Databases is betting on a single, configurable eClinical platform to help sponsors and contract research organizations (CROs) tame fragmented data, de‑risk the trial master file (eTMF), and industrialize risk‑based monitoring. Global Director of Business Development Marietta Sarkisian explains why a human‑in‑the‑loop AI “co‑pilot,” modular entry points for smaller organizations, and deep localization will be critical to keeping trials compliant, affordable, and globally connected over the next three to five years.

Clinical Trials Arena (CTA): Flex Databases has just won awards for Innovation, Product Launches, and Business Expansion. How do you interpret this recognition for the company’s current stage and direction?

Marietta Sarkisian: First of all, thank you for the acknowledgement and the awards. We are truly flattered. Second, I suppose these awards are a real reflection of the achievements we have made in recent years. We had a huge leap in our product development, and we surely keep moving forward with ambitious goals on our minds.

CTA: Sponsors and CROs still struggle with fragmented systems, slow study start-up, and eTMF inconsistencies. Which of these issues do you see as most damaging to timelines today, and why?

Marietta Sarkisian: All of the issues mentioned are actually part of a bigger puzzle, which is the absence of a robust and unified eClinical system in place. Fragmented data always appears when there is a disruption in data entry – be it due to the lack of a system or the use of multiple different systems to cover a single process.…